Abstract
Pharmacokinetics is the study of absorption, distribution, metabolism, and excretion of a drug over a time course. Measurement of a drug in the body is usually limited to the blood or plasma. Pharmacokinetic data analysis consists of examining plasma concentration—time data and estimating pharmacokinetic parameters that describe drug disposition. Methods used for pharmacokinetic analysis include noncompartmental analysis or pharmacokinetic modeling. Noncompartmental analysis does not depend on fitting mathematical models to the drug disposition data. Compartmental analysis is the most often used pharmacokinetic modeling approach. This chapter discusses various aspects of compartmental modeling.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
David O, Johnston A. Limited sampling strategies. Clin Pharmacokinet 2000; 39: 311–3113.
van Kesteren C, Mathjt RA, Lopez-Lazaro L, et al, A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemother Pharmacol 2001; 48: 459–466.
McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. Eur J Cancer 1996; 32A: 1518–1522.
Noncompartmental Analysis Based on Statistical Moment Theory. In: Gibaldi M, Perrier D (eds). Pharmacokinetics, 2nd Edit., revised and expanded. New York, NY: Marcel Dekker 1982, pp. 409–417.
Appendix C: Methods of Residuals. In: Gibaldi M, Perrier D (eds). Pharmacokinetics, 2nd Edit., revised and expanded. New York, NY: Marcel Dekker 1982, pp. 433–444.
Pharmacokinetic concepts. In: Gabrielsson J, Weiner D (eds). Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications, 2nd Edit., revised and expanded. Stockholm, Sweden: Apotekarsocieteten, 1997, pp. 58–171.
Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085–3096.
Bauer KS, Kohn EC, Lush RM, et al. Pharmacokinetics and relative bioavailability of carboxyamidotriazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. J Pharmacokinet Biopharmacol 1998; 26: 673–687.
Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharmcol 1994; 22: 431–445.
Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm 1984; 12: 545–558.
Sheiner LB. Analysis of pharmacokinetic data using parametric models 1: Regression models. J Pharmacokinet Biopharm 1984; 12: 93–117.
Sheiner LB. Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual’s parameters. J Pharmacokinet Biopharm 1985; 13: 515–540.
Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454–1457.
Jusko WJ. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol 1989; 29: 488–493.
McLeod HL, Kearns CM, Kuhn JG, et al. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998; 42: 155–159.
Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996; 37: 195–202.
Baker SD, Wirth M, Statkeveich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5: 309–317.
Rudek MA, Donehower RC, Rowinsky EK, et al. Temozolomide in patients with advanced cancer: a phase I and pharmacokinetic study. Pharmacotherapy 2004; 24: 16–25.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Baker, S.D., Rudek, M.A. (2004). Pharmacokinetic Modeling. In: Figg, W.D., McLeod, H.L. (eds) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-734-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-734-5_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5345-5
Online ISBN: 978-1-59259-734-5
eBook Packages: Springer Book Archive